期刊文献+

紫杉醇脂质体联合顺铂治疗32例晚期非小细胞肺癌的疗效分析 被引量:2

Analysis of therapeutic effects of paclitaxel liposome combined with cisplatin for treating advanced non-small cell lung cancer
下载PDF
导出
摘要 目的 观察紫杉醇酯质体联合顺铂治疗晚期非小细胞肺癌(NSCLC)的临床疗效和毒副反应.方法 32例有可测量病灶,无法手术切除或术后复发、远处转移的晚期NSCLC患者均采用紫杉醇酯质体联合顺铂方案化疗,21d为一个周期.每化疗2个周期,对可测量病灶行CT或MRI检查以评价疗效,并记录化疗期间毒副反应发生情况.结果 总有效率为40.6%,其中初治者有效率为47.1%,复治者有效率为33.3%,2者比较差异有统计学意义;病理类型中腺癌有效率为42.1%,鳞癌有效率为41.6%,二者比较差异无统计学意义;患者的毒副反应主要为骨髓抑制、胃肠道反应和周围神经毒性,多为Ⅰ~Ⅱ级.结论 紫杉醇酯质体联合顺铂治疗晚期NSCLC疗效确切,毒副反应小,患者耐受性好,值得临床广泛推广应用. Objective To observe the clinical effects and toxic and side effects of paelitaxel liposome plus cisplatin for treating advanced non-small cell lung cancer (NSCLC).Methods Thirty-two advanced NSCLC patients with measurable focus,postoperative recurrence and distal metastasis or not capable of surgical excision were all given paclitaxel liposome plus cisplatin chemotherapy,with 21 days as one course of treatment.CT or MRI were performed on measurable focuses to evaluate the therapeutic effects every 2 cycles of chemotherapy,and the incidence of toxic and side effects during chemotherapy was recorded.Results The total effectiveness rate was 40.6 %,among whom the effective rates of initially-treated and retreatment patients were respectively 47.1% and 33.3 %.In the effectiveness rates between the two groups,the difference showed statistical significance.In terms of pathological types,the effectiveness rates of adenocarcinoma and squamous carcinoma were 42.1% and 41.6% respectively.In the effectiveness rates between the two groups,the difference showed no statistical significance.The toxic and side effects of patients mainly were myelosuppression,gastrointestinal reactions and peripheral neuropathy,mostly at grades Ⅰ-Ⅱ.Conclusion In the treatment of NSCLC,the therapeutic effects of paclitaxel liposome plus cisplatin are specific,with less toxic and side effects,and can be tolerated well,so it is worthy of extensive popularization and application in clinical practice.
出处 《实用临床医药杂志》 CAS 2013年第14期59-61,共3页 Journal of Clinical Medicine in Practice
基金 中国高校医学期刊临床专项资金(11321001)
关键词 紫杉醇酯质体 顺铂 非小细胞肺癌 毒副反应 paclitaxel liposome cisplatin non-small cell lung cancer toxic and side effects
  • 引文网络
  • 相关文献

参考文献13

  • 1张力.晚期非小细胞肺癌的二线治疗进展[J].中国肺癌杂志,2008,11(1):4-9. 被引量:25
  • 2Yah F, Li L, Deng Z, et al. Paclitaxel - liposome- mi- crobuhble complexes as ultrasound- triggered therapeutic drug delivery carriers[J]. J Control Release, 2013, 166(3) : 246.
  • 3周际昌.最新肿瘤化疗技术操作规范与并发症防治及新型药物选用手册[M].北京:中国医科大学出版社.2006.1008.
  • 4Olowokure O, Torregroza - Sanchez M P, Bedoya - Apraez I D. Gemcitabine plus Nab - Paclitaxel with chemoradiation in locally advanced pancreatic cancer (LAPC) [J ]. J Gastroin- test Oncol, 2013, 4(2): El6.
  • 5Perche F, Torchilin V P. Cancer cell spheroids as a model to evaluate chemotherapy protocols [ J ]. Cancer Biol Ther, 2012, 13(12): 1205.
  • 6Rosell R, Gatzemeier U, Betticher D C, et al. Phase ran- domized trial comparing paclitaxel/carboplatin with paclitax- el/cisplatin in patients with advanced - non- small - cell - lung cancer, a cooperative multinational trail[J]. Annals of Oncology, 2002, 13(10): 1539.
  • 7Videira M A, Arranja A G, Gouveia L F. Experimental de- sign towards an optimal lipid nanosystem: A new opportunity for paclitaxel - based therapeutics [ J ]. Eur J Pharm Sci, 2013, 13, 49(2): 302.
  • 8Carrara S, Petrone M C, Testoni P A, et al. Tumors and new endoscopic ultrasound - guided therapies [ J ]. World J Gastrointest Endosc, 2013, 5(4): 141.
  • 9Schmitt - Sody M, Strieth S, Krasnici S, et al. Neovascular targeting therapy paclitaxel encapsulated in cationic liposomes improves antimmoral efficacy[J]. Clin Cancer Res, 2003, 9 (6) : 2335.
  • 10Koudelka S, Turdnek J. Liposomal paclitaxel formulations [J]. J Control Release, 2012, 163(3): 322.

二级参考文献30

  • 1ROWINSKY EK. Paclitaxel pharmacology, and other tumor types[J].Semin Oncol, 1997,24(6 Suppl 19) : 1-12.
  • 2TREAT J,DAMJANOV N ,HUANG C.et al. Liposomal-encapsulated chemotherapy:preliminary, results of a phase I study of a novel liposomal paclitaxel [J] . Ontology, 2001,15 (5 Suppl 7 ) : 44-48.
  • 3STRAUBINGER RM. ARNNOLD RD, ZHOU R. et al. Antivascular arid antitumor activities of liposome-associated drugs [J].Anticancer Res. 2004,24 (2A):397-404.
  • 4CABANES A, BRIGGS KE, GOKHAI,E PC,et al. Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel[J]. Int J Oncol, 1998,12(5 ) : 1035-1040.
  • 5SHARMA A. MAYHEW E, BOEICSAK L. et al. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts[J]. Int J Cancer, 1997. 71( 1 ):103-107.
  • 6S.Niho,Y.Ichinose.T.Tamura,et al.Results of a randomized phase Ⅲ study to comparethe overall survival of gefitinib(IRESSA)versus docetaxel in Japanese patients with non-small cell lung cancer who failed one or two chemotherapy regimens.ASCO Meeting
  • 7Douillard Jean-Yves,Kim Edward,Hirsh Vera,et al.Gefitinib(IBESSA)vergns docetsxel in patients with locally advanced or metastatic non-small-cell lung can cer pre-treated with platinum-based chemotherapy:a randomized.open-label Phase Ⅲ study(INTEREST).WCLC 2007:PRS-02.
  • 8Shepherd FA,Rodrignos Pereira J,Ciuleanu T,et al.Erlotinib in previously treated non-small-cell lung cancer.N Engl J Med.2005 Jul 14;353(2):123-32.Abstracts,Jun 2007;25:18018.
  • 9Wu,Y.Zhang,L.Au,J.Sin-Kie et al.Safety of erlotinibin TRUST,a phase Ⅳ trial in patients with advanced non-small cell lung cancer(NSCLC):Initial results from the East/South East(E/SE)Asian subgroup.ASCO Meeting
  • 10Ramlau R,Gervais R,Krzakowgki M,et al.Phase Ⅲ study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer.J Clin Oncol.2006 Jun 20;24(18):2800-3807.Abstracts,Jun 2007;25:7511.

共引文献159

同被引文献11

引证文献2

二级引证文献5

;
使用帮助 返回顶部